Boston Scientific has pulled global sales of, and is no longer seeking FDA approval for, its Acurate neo2 and Acurate Prime aortic valve systems. In a May 28 Securities and Exchange Commission filing, ...

Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially discontinuing worldwide sales of its Acurate ne ...

A deep dive into the technological progress of today’s smart valves, bearings, brakes, gearboxes and actuators, and what’s next.

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

The system is available for patients whose mitral valves are not working properly due to severe mitral annular calcification.

Edwards Lifesciences (NYSE:EW) saw its shares rise by 3% following news that competitor Boston Scientific (NYSE:BSX) is ...

By encompassing the ball valve lever, these easy-to-use, adjustable lockout devices secure against inadvertent valve activation and enable lockout by up to six workers at each lockout point. The ...

One-year follow-up data suggest that a novel transcatheter tricuspid valve replacement (TTVR) device may provide another potential alternative to surgery for patients with severe tricuspid ...

Favorable mortality and heart failure hospitalization rates, along with improved functional status, observed among recipients of LuX-Valve device for severe symptomatic tricuspid regurgitation.

The Heart Valve Devices Market is witnessing a transformative phase as cardiovascular diseases (CVDs) continue to top the global mortality chart. With an aging population, lifestyle changes, and ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Top 6 Growth Opportunities in the Medical Device Industry, 2025" report has been added to ResearchAndMarkets.com's offering. The medical device ...